CELLAVISION AB (publ) Interim report for the period January 1 - March 31, 2008
Continued growth and establishment of subsidiary in Japan
  •    Net sales for the quarter increased by 10% to SEK 18.5 million (16.8).
  •    The operating result for the quarter was SEK 1.3 million (-1.0).
  •    The net result per share for the period amounted to SEK 0.05 (-0.05).
  •    Liquid assets amounted to SEK 16.1 million (7.0) at the end of the quarter.
  •    Subsidiary established in Japan. 
  •   An Icelandic hospital has placed an order. CellaVision now has clients in all five Nordic countries.

    CEO's comment
    "CellaVision's positive trend of 2007 continued into the first quarter of 2008. We can report sound sales growth and are continuing to strengthen our position in the market," says Yvonne Mårtensson, CEO of CellaVision. "A large American commercial laboratory chain has purchased the CellaVision® DM96 for 14 of their laboratories. This further validates CellaVision's belief that our technology delivers significant cost benefits to the clinical laboratory. To use the positive momentum, we will now add more sales resources in the US."
    "Following our evaluation of the Japanese market we have registered our own subsidiary in Japan. During the year we will develop the organisation in order for it to be operative when all the necessary licenses have been obtained. Thereafter we will begin focusing on sales either direct or parallel to national distributors. Our increased market activity level may negatively influence our cash balance at the end of the year."
    Yvonne Mårtensson
    CEO CellaVision AB
    For more information please contact: 
    Yvonne Mårtensson, CEO. Tel: +46 708 33 77 82, e-mail: 
    Johan Wennerholm, CFO. Tel: +46 708 33 81 68, e-mail:
    Download the report by pressing the link below.

    Interim report for the period January 1  March 31, 2008